{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T03:11:34Z","timestamp":1785208294326,"version":"3.55.0"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:00:00Z","timestamp":1714348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Circulating levels of the antiangiogenic protein vasoinhibin, a fragment of prolactin, are of interest in vasoproliferative retinopathies, preeclampsia, and peripartum cardiomyopathy; however, it is difficult to determine the circulating levels of vasoinhibin due to the lack of quantitative assays. <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study used human serum samples to assess the concentration and bioactivity of vasoinhibin using a novel enzyme-linked immunosorbent assay (ELISA) for human vasoinhibin, which employs an anti-vasoinhibin monoclonal antibody, a human umbilical vein endothelial cell (HUVEC) proliferation assay, and a chick chorioallantoic membrane (CAM) angiogenesis assay. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Serum samples from 17 pregnant women without (one group) and with preeclampsia and pregnancy induced hypertension (another group) demonstrated endogenous vasoinhibin concentrations in the range of 5\u2013340 ng\/ml. Immunoactive vasoinhibin levels were significantly higher in preeclampsia serum compared to healthy pregnancy serum (mean 63.09 \u00b1 22.15 SD vs. 19.67 \u00b1 13.34 ng\/ml, p = 0.0003), as was the bioactive vasoinhibin level as determined by the HUVEC proliferation assay (56.12 \u00b1 19.83 vs. 13.38 \u00b1 4.88 ng\/ml, p &amp;lt; 0.0001). There was a correlation between the concentration of vasoinhibin measured by ELISA and the HUVEC proliferation assay (Pearson r = 0.95, p &amp;lt; 0.0001). Healthy serum demonstrated a proangiogenic effect in the CAM assay (p &amp;lt; 0.05, compared to control), while serum from preeclamptic patients demonstrated an antiangiogenic effect (p &amp;lt; 0.05 vs. control), as did recombinant human vasoinhibin and a synthetic circular retro-inverse vasoinhibin analogue (CRIVi45-51). The antiangiogenic effects in the CAM assay and the inhibition of HUVEC proliferation were abolished by addition of the ELISA anti-vasoinhibin monoclonal antibody, but not by mouse IgG. <\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>These results demonstrate the first quantitation of endogenous vasoinhibin in human sera and the elevation of it levels and antiangiogenic activity in sera from women with preeclampsia. The development and implementation of a quantitative assay for vasoinhibin overcomes a long-standing barrier and suggests the thorough clinical verification of vasoinhibin as a relevant biomarker.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2024.1345996","type":"journal-article","created":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T04:33:35Z","timestamp":1714365215000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Immunometric and functional measurement of endogenous vasoinhibin in human sera"],"prefix":"10.3389","volume":"15","author":[{"given":"Magdalena","family":"Zamora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Ebnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Radermacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosima","family":"Brucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Waller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"Robles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bertsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Clapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Triebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.994898","article-title":"Prolactin and vasoinhibin are endogenous players in diabetic retinopathy revisited","volume":"13","author":"Triebel","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/pr.2016.241","article-title":"Higher prolactin and vasoinhibin serum levels associated with incidence and progression of retinopathy of prematurity","volume":"81","author":"Zepeda-Romero","year":"2017","journal-title":"Pediatr Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.cell.2006.12.036","article-title":"A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy","volume":"128","author":"Hilfiker-Kleiner","year":"2007","journal-title":"Cell"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-021-00664-8","article-title":"Pathophysiology and risk factors of peripartum cardiomyopathy","volume":"19","author":"Hoes","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2017.00077","article-title":"Remarks on the prolactin hypothesis of peripartum cardiomyopathy","volume":"8","author":"Triebel","year":"2017","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00893","article-title":"A dysregulation of the prolactin\/vasoinhibin axis appears to contribute to preeclampsia","volume":"10","author":"Lenke","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.111.00754","article-title":"Circulating angiogenic factors and urinary prolactin as predictors of adverse outcomes in women with preeclampsia","volume":"61","author":"Leanos-Miranda","year":"2013","journal-title":"Hypertension"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.3700662","article-title":"Elevated vasoinhibins may contribute to endothelial cell dysfunction and low birth weight in preeclampsia","volume":"87","author":"Gonzalez","year":"2007","journal-title":"Lab Invest"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41374-020-0432-5","article-title":"Vasoinhibin reduces joint inflammation, bone loss, and the angiogenesis and vasopermeability of the pannus in murine antigen-induced arthritis","volume":"100","author":"Ortiz","year":"2020","journal-title":"Lab Invest"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-016-2187-0","article-title":"The role of the prolactin\/vasoinhibin axis in rheumatoid arthritis: an integrative overview","volume":"73","author":"Clapp","year":"2016","journal-title":"Cell Mol Life Sci"},{"key":"B11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s10456-021-09800-x","article-title":"The HGR motif is the antiangiogenic determinant of vasoinhibin: implications for a therapeutic orally active oligopeptide","volume":"25","author":"Robles","year":"2022","journal-title":"Angiogenesis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e27318","DOI":"10.1371\/journal.pone.0027318","article-title":"The antiangiogenic 16K prolactin impairs functional tumor neovascularization by inhibiting vessel maturation","volume":"6","author":"Nguyen","year":"2011","journal-title":"PloS One"},{"key":"B13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/978-3-319-12114-7_4","article-title":"Regulation of blood vessels by prolactin and vasoinhibins","volume":"846","author":"Clapp","year":"2015","journal-title":"Adv Exp Med Biol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1210\/en.2009-0390","article-title":"Cathepsin D is the primary protease for the generation of adenohypophyseal vasoinhibins: cleavage occurs within the prolactin secretory granules","volume":"150","author":"Cruz-Soto","year":"2009","journal-title":"Endocrinology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00256.2015","article-title":"Principles of the prolactin\/vasoinhibin axis","volume":"309","author":"Triebel","year":"2015","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"114011","DOI":"10.1016\/j.ygcen.2022.114011","article-title":"A comparative phylogenetic analysis of prolactin cleavage sites for the generation of vasoinhibin in vertebrates","volume":"320","author":"Leuchs","year":"2022","journal-title":"Gen Comp Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/endo.130.3.1311239","article-title":"A specific, high affinity, saturable binding site for the 16-kilodalton fragment of prolactin on capillary endothelial cells","volume":"130","author":"Clapp","year":"1992","journal-title":"Endocrinology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1172\/JCI64365","article-title":"MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy","volume":"123","author":"Halkein","year":"2013","journal-title":"J Clin Invest"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3552","article-title":"PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin","volume":"20","author":"Bajou","year":"2014","journal-title":"Nat Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1530\/EC-18-0116","article-title":"16 kDa vasoinhibin binds to integrin alpha5 beta1 on endothelial cells to induce apoptosis","volume":"7","author":"Morohoshi","year":"2018","journal-title":"Endocr Connect"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00214","article-title":"Regulator of angiogenesis and vascular function: A 2019 update of the vasoinhibin nomenclature","volume":"10","author":"Triebel","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-09-0130","article-title":"Investigation of prolactin-related vasoinhibin in sera from patients with diabetic retinopathy","volume":"161","author":"Triebel","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/hr.2015.99","article-title":"Elevated vasoinhibin derived from prolactin and cathepsin D activities in sera of patients with preeclampsia","volume":"38","author":"Nakajima","year":"2015","journal-title":"Hypertens Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/978-1-62703-360-2_16","article-title":"Preparation of human serum for prolactin measurement by multiple reaction monitoring mass spectrometry","author":"Waybright","year":"1002","journal-title":"Methods Mol Biol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000437382.03963.88","article-title":"Task Force on Hypertension in, Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists\u2019 Task Force on Hypertension in Pregnancy","volume":"122","year":"2013","journal-title":"Obstet Gynecol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.107.107607","article-title":"Placental origins of preeclampsia: challenging the current hypothesis","volume":"51","author":"Huppertz","year":"2008","journal-title":"Hypertension"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-0305","article-title":"Urinary prolactin as a reliable marker for preeclampsia, its severity, and the occurrence of adverse pregnancy outcomes","volume":"93","author":"Leanos-Miranda","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1210\/en.133.3.1292","article-title":"The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis","volume":"133","author":"Clapp","year":"1993","journal-title":"Endocrinology"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.4.1246","article-title":"Opposing actions of intact and N-terminal fragments of the human prolactin\/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis","volume":"96","author":"Struman","year":"1999","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B30","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.reprotox.2016.11.004","article-title":"The chick embryo chorioallantoic membrane (CAM) assay","volume":"70","author":"Ribatti","year":"2017","journal-title":"Reprod Toxicol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.645085","article-title":"Development of vasoinhibin-specific monoclonal antibodies","volume":"12","author":"Muller","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.18926\/AMO\/40133","article-title":"Expression of antiangiogenic prolactin fragments in the placentas of women with pregnancy induced hypertension","volume":"64","author":"Masumoto","year":"2010","journal-title":"Acta Med Okayama"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2007.54","article-title":"A protocol for isolation and culture of human umbilical vein endothelial cells","volume":"2","author":"Baudin","year":"2007","journal-title":"Nat Protoc"},{"key":"B34","doi-asserted-by":"publisher","first-page":"17111","DOI":"10.1038\/s41598-018-35383-7","article-title":"Vasoinhibin comprises a three-helix bundle and its antiangiogenic domain is located within the first 79 residues","volume":"8","author":"Robles","year":"2018","journal-title":"Sci Rep"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0712168105","article-title":"A chemical method for fast and sensitive detection of DNA synthesis in vivo","volume":"105","author":"Salic","year":"2008","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B36","doi-asserted-by":"publisher","first-page":"prot5557","DOI":"10.1101\/pdb.prot5557","article-title":"Labeling nuclear DNA with hoechst 33342","volume":"1","author":"Chazotte","year":"2011","journal-title":"Cold Spring Harb Protoc"},{"key":"B37","doi-asserted-by":"publisher","first-page":"R100","DOI":"10.1186\/gb-2006-7-10-r100","article-title":"CellProfiler: image analysis software for identifying and quantifying cell phenotypes","volume":"7","author":"Carpenter","year":"2006","journal-title":"Genome Biol"},{"key":"B38","doi-asserted-by":"crossref","DOI":"10.1007\/978-90-481-3845-6","volume-title":"The Chick Embryo Chorioallantoic Membrane in the Study of Angiogenesis and Metastasis","author":"Ribatti","year":"2010"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1160\/TH04-02-0073","article-title":"Histidine-proline rich glycoprotein (HPRG) binds and transduces anti-angiogenic signals through cell surface tropomyosin on endothelial cells","volume":"92","author":"Guan","year":"2004","journal-title":"Thromb Haemost"},{"key":"B40","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s10456-018-9637-2","article-title":"Angiogenic capacity in pre-eclampsia and uncomplicated pregnancy estimated by assay of angiogenic proteins and an in vitro vasculogenesis\/angiogenesis test","volume":"22","author":"Virtanen","year":"2019","journal-title":"Angiogenesis"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14210","article-title":"Cabergoline treatment promotes myocardial recovery in peripartum cardiomyopathy","volume":"10","author":"Pfeffer","year":"2023","journal-title":"ESC Heart Fail"},{"key":"B42","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1167\/tvst.9.9.27","article-title":"Levosulpiride increases the levels of prolactin and antiangiogenic vasoinhibin in the vitreous of patients with proliferative diabetic retinopathy","volume":"9","author":"Nunez-Amaro","year":"2020","journal-title":"Transl Vis Sci Technol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2017.00342","article-title":"From bench to bedside: translating the prolactin\/vasoinhibin axis","volume":"8","author":"Triebel","year":"2017","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/nm1108-1187","article-title":"Angiogenesis factors and preeclampsia","volume":"14","author":"Dechend","year":"2008","journal-title":"Nat Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.116.07378","article-title":"Placental growth factor: A step forward in the search for a treatment for preeclampsia","volume":"67","author":"Hilliard","year":"2016","journal-title":"Hypertension"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1126\/science.1111726","article-title":"Latest advances in understanding preeclampsia","volume":"308","author":"Redman","year":"2005","journal-title":"Science"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1172\/JCI17189","article-title":"Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia","volume":"111","author":"Maynard","year":"2003","journal-title":"J Clin Invest"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.preghy.2016.08.239","article-title":"Strong inhibitory effect of pre-eclampsia serum on angiogenesis detected in vitro by human cell-based angiogenesis tests","volume":"6","author":"Virtanen","year":"2016","journal-title":"Pregnancy Hypertens"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2362.2011.02561.x","article-title":"STrengthening the Reporting of OBservational studies in Epidemiology - Molecular Epidemiology (STROBE-ME): an extension of the STROBE statement","volume":"42","author":"Gallo","year":"2012","journal-title":"Eur J Clin Invest"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1345996\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T04:33:41Z","timestamp":1714365221000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1345996\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,29]]},"references-count":49,"alternative-id":["10.3389\/fendo.2024.1345996"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2024.1345996","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,29]]},"article-number":"1345996"}}